drugset / Trial / NCT04215016
Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, dose escalation, phase I study, aiming to evaluate the safety and efficacy of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific Chimeric Antigen Receptor (CAR) T-cells in patient with relapsed or refractory diffuse B cell lymphoma.
Timeline
- Start
- 2019-12
- Primary completion
- 2023-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells | Cell therapy | 1e+06 cells/kg | — |
| Subject | Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells | Cell therapy | 3e+06 cells/kg | — |
| Subject | Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells | Cell therapy | 8e+06 cells/kg | — |